Melbourne, Australia, 09 January 2023 – Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has been granted Chinese patent ZL 201680069543.6, entitled “Genetically modified cells and uses thereof”. This patent is part of the family represented by the international patent filing WO2017088012.
The […]
Melbourne, Victoria, Australia – 08 November 2022
The Peter MacCallum Cancer Centre (“Peter Mac”) and Cartherics Pty Ltd (“Cartherics”) announced today they have entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-001) for the treatment of cutaneous T-cell lymphoma (CTCL).
“Patients with advanced stages of cutaneous T-cell lymphomas often […]
MELBOURNE, Australia, 13 October 2022 – Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, has opened today a brand-new state-of-the-art facility to strengthen the company’s research and manufacturing capabilities, as well as support local innovation. Cartherics invested AU$4M in the newly designed and built facility, which includes PC2 and dedicated […]
MELBOURNE, Australia, 27 September 2022 – Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, together within partner institutions, has received $5.4M Medical Research Futures Fund (MRFF) grant to develop a new approach to enhance cancer therapy by engaging the patients’ own immune system to complement CAR cell therapy.
The company, in […]
On Thursday, 2 September, in an interview with Jack Hodgins on 2NUR.FM’s ‘Wellbeing’ segment, Professor Bryan Williams (Cartherics Non-Executive Board Member) spoke about COVID-19, viruses and how vaccines control them, and the importance of medical research.
“I would encourage Australians to convince their politicians that they need to increase the research budget in Australia, […]
Cartherics Pty Ltd and the Australian Regenerative Medicine Institute (ARMI), including commercialisation initiative CCRM Australia, announced agreements for closer cooperation and collaboration today.
“Cartherics affiliation with ARMI is an important step in our development and will embed industry and academic excellence in regenerative medicine and translation to clinical medicine in cancer,” said Prof Alan Trounson, Cartherics […]
Melbourne, Australia and Seoul, South Korea
28 June 2021
Cartherics Pty Ltd (“Cartherics”) and ToolGen, Inc. (“ToolGen”) announced today that they have entered into a commercial licence agreement.
Under the agreement, Cartherics obtains […]
By Hayden Smith, 7 June 2021
‘It was mid-March at Fiona Stanley Hospital in Perth, and a squadron of doctors and nurses had gathered by my bed. Some were methodically […]
By Heather Hawkins
24 May 2021
Even today – and it’s been 14 years since diagnosis – they still evoke a very raw and deeply emotional response. It was the first time I’d faced the undeniable fact […]
Four Australian women are diagnosed with ovarian cancer a day and three will eventually die from the disease. It’s usually diagnosed late, because few women show symptoms until they have advanced cancer.
As a junior doctor in London in the mid-1980s, Ian Jacobs saw women undergo chemo and […]
Cartherics’ mission is the development of novel, “off-the-shelf” (allogeneic) immune cell therapy products for the treatment of cancer.
Stay informed about our latest news and developments
© Copyright 2022 | Cartherics Pty ltd
